The results show that CD44 positivity is significantly less frequently seen in metastasis than in primary tumor; CD24 positivity is more frequently seen in metastasis for grade II cases. This indicates, that cells with stem cell phenotype decrease in metastasis reflecting heterogeneity between primary and metastatic sites, which should be taken into consideration for assessing progression and treatment.